
|Videos|August 10, 2017
Dr. Weiss on Developments in the Treatment of Head and Neck Cancer
Author(s)Jared Weiss, MD
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.
Advertisement
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.
There is a trial of pembrolizumab (Keytruda) in combination with radiation, which might one day replace cisplatin, explains Weiss.
There is also a study investigating durvalumab (Imfinzi) with carboplatin and nab-paclitaxel (Abraxane) as induction chemotherapy prior to surgery for hard-to-cure patients, states Weiss.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































